ESTABLISHMENT LABS HOLDINGS (ESTA)

VGG312491084 - Common Stock

40.01  +1.07 (+2.75%)

After market: 40.01 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ESTA. ESTA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. ESTA has a bad profitability rating. Also its financial health evaluation is rather negative. ESTA is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

ESTA had negative earnings in the past year.
In the past year ESTA has reported a negative cash flow from operations.
ESTA had negative earnings in each of the past 5 years.
In the past 5 years ESTA always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -24.98%, ESTA perfoms like the industry average, outperforming 48.66% of the companies in the same industry.
With a Return On Equity value of -215.86%, ESTA is not doing good in the industry: 78.61% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -24.98%
ROE -215.86%
ROIC N/A
ROA(3y)-31.44%
ROA(5y)-30.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 65.08%, ESTA is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
ESTA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ESTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.48%
GM growth 5Y1.89%

More info and screens

3

2. Health

2.1 Basic Checks

ESTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ESTA has more shares outstanding than it did 1 year ago.
ESTA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ESTA has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.07, we must say that ESTA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.07, ESTA is in line with its industry, outperforming 48.13% of the companies in the same industry.
A Debt/Equity ratio of 5.94 is on the high side and indicates that ESTA has dependencies on debt financing.
ESTA has a worse Debt to Equity ratio (5.94) than 89.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.94
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACCN/A
WACC8.65%

2.3 Liquidity

ESTA has a Current Ratio of 3.62. This indicates that ESTA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.62, ESTA is doing good in the industry, outperforming 65.24% of the companies in the same industry.
A Quick Ratio of 2.29 indicates that ESTA has no problem at all paying its short term obligations.
ESTA has a Quick ratio (2.29) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 2.29

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.86% over the past year.
ESTA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.71%.
ESTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.96% yearly.
EPS 1Y (TTM)7.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.32%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y24.93%
Revenue growth 5Y21.96%
Sales Q2Q%4.47%

3.2 Future

Based on estimates for the next years, ESTA will show a very strong growth in Earnings Per Share. The EPS will grow by 20.18% on average per year.
The Revenue is expected to grow by 25.79% on average over the next years. This is a very strong growth
EPS Next Y17.69%
EPS Next 2Y17.87%
EPS Next 3Y18.38%
EPS Next 5Y20.18%
Revenue Next Year0.92%
Revenue Next 2Y11.84%
Revenue Next 3Y15.96%
Revenue Next 5Y25.79%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ESTA's earnings are expected to grow with 18.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.87%
EPS Next 3Y18.38%

More info and screens

0

5. Dividend

5.1 Amount

ESTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESTABLISHMENT LABS HOLDINGS

NASDAQ:ESTA (12/20/2024, 8:07:35 PM)

After market: 40.01 0 (0%)

40.01

+1.07 (+2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners89.39%
Inst Owner Change0.53%
Ins Owners7.26%
Ins Owner Change-0.52%
Market Cap1.12B
Analysts84.62
Price Target61.49 (53.69%)
Short Float %19.91%
Short Ratio11.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.39%
Min EPS beat(2)-18.72%
Max EPS beat(2)5.95%
EPS beat(4)3
Avg EPS beat(4)4.29%
Min EPS beat(4)-18.72%
Max EPS beat(4)15%
EPS beat(8)6
Avg EPS beat(8)5.29%
EPS beat(12)7
Avg EPS beat(12)-25.58%
EPS beat(16)9
Avg EPS beat(16)-22.19%
Revenue beat(2)1
Avg Revenue beat(2)-1.07%
Min Revenue beat(2)-2.5%
Max Revenue beat(2)0.36%
Revenue beat(4)2
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.5%
Max Revenue beat(4)1.21%
Revenue beat(8)4
Avg Revenue beat(8)-1.14%
Revenue beat(12)7
Avg Revenue beat(12)0.25%
Revenue beat(16)11
Avg Revenue beat(16)2.03%
PT rev (1m)-7.82%
PT rev (3m)-3.03%
EPS NQ rev (1m)-14.5%
EPS NQ rev (3m)-137.89%
EPS NY rev (1m)-3.19%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)-8.4%
Revenue NQ rev (3m)-13.79%
Revenue NY rev (1m)-2.55%
Revenue NY rev (3m)-4.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.32
P/FCF N/A
P/OCF N/A
P/B 34.25
P/tB 49.87
EV/EBITDA N/A
EPS(TTM)-2.58
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS5.47
BVpS1.17
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.98%
ROE -215.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.08%
FCFM N/A
ROA(3y)-31.44%
ROA(5y)-30.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.48%
GM growth 5Y1.89%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 5.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 311.7%
Cap/Sales 12.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 2.29
Altman-Z 1.07
F-Score3
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)551.89%
Cap/Depr(5y)394.77%
Cap/Sales(3y)13.79%
Cap/Sales(5y)10.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.32%
EPS Next Y17.69%
EPS Next 2Y17.87%
EPS Next 3Y18.38%
EPS Next 5Y20.18%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y24.93%
Revenue growth 5Y21.96%
Sales Q2Q%4.47%
Revenue Next Year0.92%
Revenue Next 2Y11.84%
Revenue Next 3Y15.96%
Revenue Next 5Y25.79%
EBIT growth 1Y4.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.59%
EBIT Next 3Y32.09%
EBIT Next 5Y32.27%
FCF growth 1Y12.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.11%
OCF growth 3YN/A
OCF growth 5YN/A